Paul Tudor Jones Tudor Investment Corp
Paul Tudor Jones is the founder of Tudor Investment Corporation and a pioneering macro trader. He rose to prominence after navigating the 1987 market crash successfully and has since built a multi-strategy firm spanning global markets. Jones is widely associated with discretionary macro trading, risk management discipline, and high-profile philanthropic efforts in education and the environment.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$662M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$116M |
| 3 |
Broadcom
AVGO
|
+$96.2M |
| 4 |
Walmart Inc
WMT
|
+$91.2M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$77.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Bitcoin Trust
IBIT
|
+$175M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$152M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$149M |
| 4 |
INFN
Infinera Corporation Common Stock
INFN
|
+$108M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$70.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.92% |
| 2 | Financials | 4.33% |
| 3 | Healthcare | 3.85% |
| 4 | Consumer Discretionary | 3.59% |
| 5 | Industrials | 3.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Prime Medicine
PRME
$589M
| $120K | ﹤0.01% |
+60,368
| New | +$154K |
|
2927
PUT
Constellium
CSTM
$3.61B
| $119K | ﹤0.01% |
11,800
-2,200
| -16% | -$23.4K |
|
2928
CALL
Elanco Animal Health
ELAN
$12.2B
| $119K | ﹤0.01% |
+11,300
| New | +$128K |
|
2929
Amylyx Pharmaceuticals
AMLX
$4.25B
| $118K | ﹤0.01% |
33,428
-259
| -0.8% | -$922 |
|
2930
PUT
Warner Bros
WBD
$72B
| $116K | ﹤0.01% |
+10,800
| New | +$113K |
|
2931
Village Farms International
VFF
$331M
| $115K | ﹤0.01% |
189,300
| – | – |
|
2932
Senseonics Holdings Inc
SENS
$496M
| $114K | ﹤0.01% |
8,719
| – | – |
|
2933
Purple Innovation
PRPL
$23.4M
| $114K | ﹤0.01% |
6,026
| – | – |
|
2934
Tyra Biosciences
TYRA
$1.56B
| $112K | ﹤0.01% |
12,093
-3,484
| -22% | -$45.1K |
|
|
2935
PUT
Elanco Animal Health
ELAN
$12.2B
| $107K | ﹤0.01% |
+10,200
| New | +$115K |
|
2936
PUT
Western Union
WU
$2.28B
| $107K | ﹤0.01% |
+10,100
| New | +$107K |
|
2937
Precigen
PGEN
$2.57B
| $106K | ﹤0.01% |
71,464
| – | – |
|
2938
IAMGOLD
IAG
$12.4B
| $106K | ﹤0.01% |
17,011
-1,975
| -10% | -$11.7K |
|
|
ITOS
2939
DELISTED
iTeos Therapeutics
ITOS
| $105K | ﹤0.01% |
+17,651
| New | +$130K |
|
2940
Allogene Therapeutics
ALLO
$701M
| $104K | ﹤0.01% |
+71,008
| New | +$134K |
|
2941
CALL
Cushman & Wakefield Ltd
CWK
$3.44B
| $102K | ﹤0.01% |
+10,000
| New | +$122K |
|
|
LPRO
2942
DELISTED
Open Lending Corp
LPRO
| $98.3K | ﹤0.01% |
+35,607
| New | +$177K |
|
2943
PUT
Bloomin' Brands
BLMN
$980M
| $92.5K | ﹤0.01% |
12,900
-9,000
| -41% | -$95.4K |
|
2944
PLAYSTUDIOS Inc
MYPS
$60.3M
| $90K | ﹤0.01% |
70,871
-208
| -0.3% | -$338 |
|
2945
4D Molecular Therapeutics
FDMT
$850M
| $82K | ﹤0.01% |
25,399
-2,035
| -7% | -$9.59K |
|
2946
ImmunityBio
IBRX
$8.03B
| $73K | ﹤0.01% |
+24,253
| New | +$73.5K |
|
|
GAN
2947
DELISTED
GAN Ltd
GAN
| $71.6K | ﹤0.01% |
40,436
| – | – |
|
2948
Lyell Immunopharma
LYEL
$361M
| $66.9K | ﹤0.01% |
6,216
| – | – |
|
2949
PUT
Green Plains
GPRE
$1.05B
| $66.4K | ﹤0.01% |
13,700
-36,800
| -73% | -$264K |
|
2950
CALL
Aspen Aerogels
ASPN
$416M
| $63.9K | ﹤0.01% |
+10,000
| New | +$96.4K |
|
Similar funds
Paul Tudor Jones's Q1 2025 Portfolio in Review
As of Q1 2025, Paul Tudor Jones held 3,818 positions worth $30.1B, up 15% from $26.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Paul Tudor Jones deployed $6.13B of net new capital in Q1 2025, opening 874 new positions and adding to 1,161 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 621,815 shares worth $82M.
By sector, the portfolio is most concentrated in Technology at 5.9% of assets, down from 6.4% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was iShares Bitcoin Trust, an estimated $175M trimmed.
- Paul Tudor Jones's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 621,815 shares worth $82M.
- Paul Tudor Jones added most to iShares Russell 2000 ETF in Q1 2025, an estimated $662M increase.
- Paul Tudor Jones's biggest Q1 2025 reduction was iShares Bitcoin Trust, cutting an estimated $175M.
- Paul Tudor Jones fully exited Infinera Corporation Common Stock in Q1 2025, selling an estimated $108M.
- Paul Tudor Jones's ten largest holdings make up 40% of its $30.1B portfolio in Q1 2025.
- Paul Tudor Jones opened 874 new positions and closed 844 in Q1 2025.
- Paul Tudor Jones's portfolio value rose 15% quarter-over-quarter to $30.1B.
Based on Tudor Investment Corp's 13F filing for Q1 2025, filed 15 May 2025.